glp-1 colorectal cancer mortality study november 2025 Long-term risk in users of agonists in Denmark: a nationwide emulated trial Dr. Rhonda Patrick on X:

Symptoms of DVT ( usually in one leg): Swelling: One leg looks larger than the other

adults will qualify as obese by 2030 and nearly 25% as severely obese.i GLP-1s should be a key tool in managing obesity outcomes and costs: Despite higher prescription costs relative to nonusers, persistent GLP-1 use can decrease average annual total cost of care by $14K-$15K (14%) among chronically obese patients in the first one to two years of use

Use of peptides (or any drug) has the potential to permanently change how your body works

Balancing blood sugar and controlling appetite : Tirzepatide is a GLP-1 receptor agonist that mimics the bodys natural GLP-1 hormone and plays a crucial role in regulating blood sugar, suppressing appetite, and improving metabolism

Progress in Oklahoma and Continued Need Recent data from the Oklahoma State Department of Health shows encouraging improvements in adult and childhood obesity rates across the state